Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2013-02-19 21:28:27
Reporting Period:
Filing Date:
Accepted Time:
2013-02-19 21:28:27
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
850693 Allergan Inc AGN Pharmaceutical Preparations (2834) 951622442
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1298861 M Trevor Jones 2525 Dupont Drive
Irvine CA 92612
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-02-15 1,000 $60.60 14,327 No 4 M Direct
Common Stock Disposition 2013-02-15 2,000 $107.82 12,327 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Nonemployee Director Stock Option (Right to Buy) Disposition 2013-02-15 1,000 $0.00 1,000 $60.60
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
3,400 2017-05-01 No 4 M Direct
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 22, 2012.
  2. Includes 4,800 shares of the Issuer's common stock underlying the RSUs awarded.
  3. Includes shares issued pursuant to the dividend equivalent rights, exempt transaction under Rule 16a-11.
  4. Option is fully vested and exercisable on the date of the next regular annual meeting of stockholders of Allergan, Inc. at which directors are to be elected following the date of grant.